Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company developing nomlabofusp for Friedreich's ataxia, a rare genetic disease that causes progressive disability. The company is focused on advancing the drug through clinical development and regulatory review, with an eventual goal of commercialization if approved.

2.19

2.19

— Larimar Therapeutics, Inc.
%
Lead drug candidate100% Nomlabofusp is the company's main investigational therapy for Friedreich's ataxia.
Clinical development programs0% Open label and extension studies generate the clinical evidence needed for regulatory review.
Formulation development0% Work to transition from frozen solution to lyophilized product for commercialization.

Larimar does not currently sell commercial products; its near-term 'customers' are clinical trial participants,...

  • Clinical trial participants with Friedreich's ataxiaprimary

    Patients enroll in studies to access investigational therapy and contribute efficacy and safety data.

  • Regulatory agenciesprimary

    FDA, EMA, and MHRA review the development package, endpoint strategy, and safety data.

  • Future rare-disease prescribers and patientsemerging

    If approved, neurologists and FA patients would use nomlabofusp as a disease-targeted therapy.

  • Potential strategic partnerssecondary

    Partners may provide capital, development support, or commercialization capabilities.

Larimar is based in the United States and its development work is centered on U.S. regulatory interactions, especially...

  • •United States is the core operating and regulatory base
  • •FDA interactions are central to the accelerated approval strategy
  • •EMA and MHRA discussions support broader rare-disease development
  • •No product sales geography yet because the company is pre-revenue
  • •Future commercialization could expand beyond the U.S. if approved

The company is focused on advancing nomlabofusp toward regulatory approval, including continued interaction with FDA...

01
Regulatory path for accelerated approvalshort-term

FDA alignment on endpoint strategy and safety package is critical to shorten time to market.

02
Clinical development of nomlabofuspshort-term

Clinical data are needed to support efficacy, safety, and eventual commercialization.

03
Commercial formulation readinessmedium-term

The lyophilized product is intended for commercialization and must be validated in development.

04
Capital preservation and financing flexibilityshort-term

As a pre-revenue biotech, the company must fund ongoing R&D until approval or partnership.

Larimar faces the typical risks of a single-asset, pre-revenue biotech: clinical failure, regulatory delay, and...

critical

Clinical development failure

The company has no approved products, so value depends on nomlabofusp succeeding in trials.

Scope
Lead asset nomlabofusp
Materiality
high
high

Regulatory endpoint uncertainty

Accelerated approval may depend on FDA accepting FXN concentration as a surrogate endpoint.

Scope
BLA strategy and approval timing
Materiality
high
high

Financing risk

The company is pre-revenue and expects to fund operations through external capital.

Scope
Cash runway into 2026
Materiality
high
medium

Manufacturing and formulation execution

Commercialization depends on successful transition to the lyophilized formulation.

Scope
Drug product comparability and scale-up
Materiality
medium
medium

Rare-disease trial execution

Small patient populations make enrollment, retention, and endpoint interpretation difficult.

Scope
FA clinical studies
Materiality
medium
Research and development accruals
Can shift quarterly R&D expense and operating loss
Stock-based compensation
Affects reported operating expenses and net loss
Going-concern and liquidity disclosures
Important for assessing dilution and runway

CAPRICOR THERAPEUTICS, INC.

CAPR · Pharmaceutical Preparations

Longeveron Inc.

LGVN · Pharmaceutical Preparations

Lyra Therapeutics, Inc.

LYRA · Surgical & Medical Instruments & Apparatus

Kalaris Therapeutics, Inc.

KLRS · Biological Products, (No Diagnostic Substances)

Citius Pharmaceuticals, Inc.

CTXR · Pharmaceutical Preparations

LadRx Corp

Biological Products, (No Diagnostic Substances)

: 28.4.2026